Patent Yard Sign in
Expired Canadian patentCanada

Oral drug delivery system

CA 2810477 C · Owner: Durect Corporation · Inventors: Yum, Su Il; Gibson, John W.; Schoenhard, Grant

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

Drug formulations, dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions including oral administration are provided. Embodiments of this invention provide an oral formulation comprising: a drug component; sucrose acetate isobutyrate (SAIB); and a cellulose acetate butyrate (CAB) having a butyryl content ranging from about 17% to about 38% an acetyl content ranging from about 13% to about 30% a hydroxyl content ranging from about 0.8% to about 1.7% or a combination thereof.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed December 15, 2003 and granted September 17, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 15, 2023.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 15, 2025.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledDecember 15, 2003
GrantedSeptember 17, 2013
Term endedDecember 15, 2023
Patent numberCA 2810477 C
Classification (IPC)A61K47/38 +2 more

Timeline

Timeline From CIPO dates

2004200620082010201220142016201820202022Application filedDec 15, 2003Patent grantedSep 17, 2013Term endedDec 15, 2023

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.